The incretin system and type 2 diabetes

US Endocrinology

Volumn 5, Issue , 2009, Pages 57-62

  Barnett, Anthony H ^a  

^a UNIVERSITY HOSPITALS BIRMINGHAM NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Dipeptidyl peptidase 4 (DPP 4); DPP 4 inhibitor; Exenatide; GLP 1 receptor agonist; Glucagon like peptide 1 (GLP 1); Incretin; Liraglutide; Saxagliptin; Sitagliptin; Type 2 diabetes

Indexed keywords

EID: 84857432374     PISSN: 17583918     EISSN: 17583926     Source Type: Journal    
DOI: 10.17925/use.2009.05.1.57     Document Type: Article

References (53)

1. Centers for Disease Control and Prevention, National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2007, Atlanta, GA, US Department of Health and Human Services, Centers for Disease Control and Prevention, 2008
2. International Diabetes Federation. The Diabetes Atlas, third edition, IDF, 2008. Available at: www.eatlas.idf.org/ (accessed November 30, 2009).
3. Nauck M, Stöckmann F, Ebert R, et al, Reduced incretin effect in type 2 (non-insulin-dependent) diabetes, Diabetologia, 1986;29:46-52
4. Nauck MA, Heimesaat MM, Orskov C, et al., Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type-2 diabetes mellitus, J Clin Invest, 1993;91: 301-7.
5. Nauck MA, Kleine N, Orskov C, et al., Normalization of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 (non-insulin-dependent) diabetic patients, Diabetologia, 1993;36:741-4.
6. Aaboe K, Krarup T, Madsbad S, et al., GLP-1: physiological effects and potential therapeutic applications, Diabetes Obes Metab, 2008;10:994-1003.
7. Flint A, Raben A, Astrup A, et al., Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans, J Clin Invest, 1998;101:515-20.
8. Gutzwiller JP, Tschopp S, Bock A, et al., Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulinresistant obese men, J Clin Endocrinol Metab, 2004;89:3055-61.
9. Nyström T, The potential beneficial role of glucagon-like peptide-1 in endothelial dysfunction and heart failure associated with insulin resistance, Horm Metab Res, 2008;40: 593-606
10. Bose AK, Mocanu MM, Carr RD, et al., Glucagon-like peptide 1 can directly protect the heart against ischemia/ reperfusion injury, Diabetes, 2005;54:146-51.
11. Nikolaidis LA, Mankad S, Sokos GG, et al., Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion, Circulation, 2004;109:962-5.
12. Vilsbøll T, Brock B, Perrild H, et al., Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with type 2 diabetes mellitus, Diabet Med, 2008;25:152-6.
13. Drucker DJ, Nauck MA, The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes, Lancet, 2006;368(9548): 1696-1705
14. Mentlein R, Dipeptidyl-peptidase IV (CD26) - role in the inactivation of regulatory peptides, Regul Pept, 1999;85:9-24
15. Exenatide (BYETTA®), US SPC (2008), Amylin Pharmaceuticals Inc, San Diego, CA, USA and Eli Lilly and Company, Indianapolis, IN, US
16. Gryskiewicz KA, Coleman CI, Focus on exenatide. A novel incretin mimetic hormone for the treatment of type 2 diabetes, Formulary, 2005;40:86-90.
17. Exenatide (BYETTA®), EU SPC (2009), Eli Lilly Nederland BV, Houten, The Netherlands
18. Kolterman O, Kim DD, Shen L, et al., Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus, Am J Health Syst Pharm, 2005;62: 173-81.
19. Madsbad S, Treatment of type 2 diabetes with incretin-based therapies, Lancet, 2008;373:438-9
20. Kim D, MacConell L, Zhuang D, et al., Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes, Diabetes Care, 2007;30:1487-93.
21. Drucker DJ, Buse JB, Taylor K, et al., for the DURATION-1 Study Group, Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study, Lancet, 2008;372:1240-50.
22. Liraglutide (VICTOZA®), EU SPC (2009), Novo Nordisk A/S, Bagsværd, Denmark
23. Steensgaard DB, Thomsen JK, Olsen HB, et al., The molecular basis for the delayed absorption of the once-daily human GLP-1 analoge, liraglutide, Diabetes, 2008;57(Suppl. 1):A164 (552-P).
24. Elbrønd B, Jakobsen G, Larsen S, et al., Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects, Diabetes Care, 2002;25:1398-1404.
25. Agersø H, Jensen LB, Elbrond B, et al., The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP1 derivative, in healthy men, Diabetologia, 2002;45:195-202.
26. DeFronzo RA, Ratner RE, Han J, et al., Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes, Diabetes Care, 2005;28:1092-1100.
27. Buse JB, Henry RR, Han J, et al.; Exenatide-113 Clinical Study Group, Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes, Diabetes Care, 2004;27:2628-35.
28. Kendall DM, Riddle MC, Rosenstock J, et al., Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea, Diabetes Care, 2005;28:1083-91.
29. Barnett AH, Burger J, Johns D, et al., Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial, Clin Ther, 2007;29: 2333-48.
30. Heine RJ, Van Gaal LF, Johns D, et al. GWAA Study Group, Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial, Ann Intern Med, 2005;143:559-69.
31. Nauck MA, Duran S, Kim D, et al., A comparison of twicedaily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study, Diabetologia, 2007;50:59-67.
32. Amori RE, Lau J, Pittas AG, Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and metaanalysis, JAMA, 2007;298:194-206
33. Buse JB, Klonoff DC, Nielsen LL, et al., Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials, Clin Ther, 2007;29:139-53.
34. Marre M, Shaw J, Brändle M, et al., Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with type 2 diabetes (LEAD-1 SU), Diabetic Medicine, 2009;26:268-78.
35. Nauck MA, Frid A, Hermansen K, et al., Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin in type 2 diabetes, Diabetes Care, 2009;32:84-90.
36. Garber A, Henry R, Ratner R, et al., Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): randomised, 52-week, phase III, double-blind, parallel-treatment trial, Lancet, 2009;373:473-81.
37. Zinman B, Gerich J, Buse J, et al., Efficacy and safety of the human GLP-1 analog liraglutide in combination with metformin and TZD in patients with type 2 diabetes mellitus (LEAD-4 Met+TZD), Diabetes Care, 2009;32:1224-30.
38. Russell-Jones D, Vaag A, Schmitz O, et al., on behalf of the LEAD-5 (Liraglutide Effect and Action in Diabetes 5) met+SU Study Group, Liraglutide vs insulin glargine and placebo in combination with metformin and sulphonylurea therapy in type 2 diabetes mellitus: a randomised controlled trial (LEAD-5 met+SU), Diabetologia, 2009;52:2046-55.
39. Buse J, Rosenstock J, Sesti G, et al., for the LEAD 6 study group, Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6), Lancet, 2009;374(9683):39-47.
40. Moretto TJ, Milton DR, Ridge TD, et al., Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study, Clin Ther, 2008;30:1448-60.
41. Fineman MS, Shen LZ, Taylor K, et al., Effectiveness of progressive dose-escalation of exenatide (exendin-4) in reducing dose-limiting side effects in subjects with type 2 diabetes, Diabetes Metab Res Rev, 2004;20:411-17.
42. Irie S, Matsumura Y, Zdravkovic M, et al., Tolerability, pharmacokinetics and pharmacodynamics of the oncedaily human GLP-1 analog liraglutide in Japanese healthy subjects: a randomized, double-blind, placebo-controlled dose-escalation study, Int J Clin Pharmacol Ther, 2008;46: 273-9.
43. Nathan DM, Buse JB, Davidson MB, et al.; American Diabetes Association; European Association for Study of Diabetes, Medical management of hyperglycemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes, Diabetes Care, 2009;32:193-203.
44. Sitagliptin (JANUVIA®), US SPC (2008), Merck & Co Inc, Whitehouse Station, NJ 08889, US
45. Herman GA, Stevens C, Van Dyck K, et al., Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: results from two randomized, double-blind, placebo-controlled studies with single oral doses, Clin Pharmacol Ther, 2005;78: 675-88.
46. Herman GA, Bergman A, Liu F, et al., Pharmacokinetics and pharmacodynamic effects of the oral DPP-4 inhibitor sitagliptin in middle-aged obese subjects, J Clin Pharmacol, 2006;46:876-86.
47. Bergman AJ, Stevens C, Zhou Y, et al., Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers, Clin Ther, 2006;28:55-72.
48. Goldstein BJ, Feinglos MN, Lunceford JK, et al.; Sitagliptin 036 Study Group, Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes, Diabetes Care, 2007;30:1979-87.
49. Riche DM, East HE, Riche KD, Impact of sitagliptin on markers of beta-cell function: a meta-analysis, Am J Med Sci, 2009;337:321-8
50. Rosenstock J, Aguilar-Salinas C, Klein E, et al.; for the CV181-011 Study Investigators, Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes, Curr Med Res Opin, 2009;25:2401-11.
51. Chacra AR, Tan GH, Apanovitch A, et al., Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial, Int J Clin Pract, 2009;63:1395-1406.
52. Defronzo RA, Hissa MN, Garber AJ, et al.; for the Saxagliptin 014 Study Group, The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes on metformin alone, Diabetes Care, 2009;32:1649-55.
53. Saxagliptin (ONGLYZA®), US SPC (2009), Bristol-Myers Squibb Company, Princeton, NJ, USA and AstraZeneca Pharmaceuticals LP, Wilmington, DE, US